|
|
 |
|
Viewing report
|
|
|
|
Nocturnal Enuresis Therapeutics - Pipeline Assessment and Market Forecasts to 2017
GlobalData, Aug 2011, Pages: 40
Nocturnal Enuresis Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Nocturnal Enuresis Therapeutics - Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global NE therapeutics market. The report identifies the key trends shaping and driving the global NE therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global NE sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
According to GlobalData estimates, the global nocturnal enuresis (NE) therapeutics market valued $164.6m in 2010 is forecast to grow at a compound annual growth rate (CAGR) of 2.9% over the next seven years, to reach $201.0m by 2017. The current NE therapeutics market is primarily driven by generics, and desmopressin acetate, a synthetic analog of antidiuretic hormone (ADH) forms the first line of therapy for the pharmacological treatment of NE. The drugs that form the second line of treatment for NE include tricyclic antidepressants (TCA) such as imipramine and anticholinergics such oxybutynin. The patent expiry of the desmopressin acetate tablet in 2005 had a negative impact on the NE therapeutics market. There are no clinical trials being conducted specifically for NE; however trials are ongoing for urinary incontinence (UI) and overactive bladder. This indicates that the launch of any novel drug is not anticipated during the forecast period. Therefore, there is no major factor that would drive the growth of the NE therapeutics market during the forecast period, resulting in overall slow market growth.
Scope
The report provides information on the key drivers and challenges of the NE therapeutics market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) NE therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Analysis of the current and future competition in the seven key countries NE therapeutics market. Key market player covered is Ferring Pharmaceuticals.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the NE therapeutics market.
- Analysis of key recent licensing and partnership agreements in NE therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global NE therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global NE therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global NE therapeutics market landscape? – Identify, understand and capitalize.
|
|
|
|
